Login to Your Account



Financings Roundup


Monday, October 17, 2011
Urigen Pharmaceuticals Inc., of Walnut Creek, Calif., said it received $300,000 in a financing transaction in the form of two-year convertible notes. Proceeds will be used primarily for general corporate purposes, including supporting the activities required to bring the company into compliance with SEC reporting requirements and to advance development of lead program URG101, in interstitial cystitis/painful bladder syndrome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription